Does first-line surgery still have its place in the treatment of acromegaly?
Transsphenoidal surgery is currently the first-line treatment of acromegaly. Remission is observed in 80 to 90% microadenomas, 50 to 60% non-invasive macroadenomas, and less than 20% invasive macroadenomas. Predictive factors include age, maximal size of the adenoma, cavernous sinus invasion, initial hormone levels and neurosurgeon's experience. Complications are rare, with about 5% definitive diabetes insipidus and 10% of new anterior pituitary hormone deficits. Somatostatin agonist pretreatment can be proposed as it decreases tumor volume in about 25% cases and might reduce the rate of immediate postsurgical complications; however, there is no obvious difference in surgical remission rate whether patients are pretreated or not. Debulking surgery can also be proposed in very large macroadenomas incompletely controlled by somatostatin agonists or resistant to medical treatment, as it was shown to facilitate somatostatin agonist efficacy in more than 50% cases.
Service d'endocrinologie, diabète et maladies métaboliques, centre de référence des maladies rares d'origine hypophysaire, hôpital de la Timone, Assistance publique-Hôpitaux de Marseille, université de la méditerranée, Marseille, France. fredcast@umich.edu
F
F
Castinetti
I
I
Morange
N
N
Dubois
F
F
Albarel
B
B
Conte-Devolx
H
H
Dufour
T
T
Brue
D000172:Acromegaly / Q000209:etiology / Q000601:surgery*; D006801:Humans; D019635:Neurosurgical Procedures; D010911:Pituitary Neoplasms / Q000150:complications / Q000601:surgery; D013004:Somatostatin / Q000819:agonists
D013004:Somatostatin